3. Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE: PFE) ranks third among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and this is one of the most globally recognized pharmaceutical companies in the market. Trading at $24.29, with the stock up 2.60%, Pfizer Inc. (NYSE: PFE) is backed by 83 hedge fund holders, showing that investors continue to watch the company closely despite a more difficult post-pandemic reset. For investors searching for pharmaceutical stocks, healthcare stocks to buy, biotech stocks, oncology stocks, drug development stocks, and AI-powered healthcare stocks, Pfizer Inc. (NYSE: PFE) remains important because it operates at global scale and continues to compete in some of the most important areas of medicine, including oncology, vaccines, immunology, internal medicine, and specialty care.
On June 23, Reuters reported that Pfizer Inc. (NYSE: PFE)’s Chief International Commercial Officer, Alexandre de Germay, said China has moved ahead of Europe in pharmaceutical innovation and drug development. That statement is important because it reflects a major shift in the global drug development landscape. For decades, investors typically viewed the United States and Europe as the dominant centers of pharmaceutical innovation. But China has rapidly expanded its clinical research capabilities, biotechnology ecosystem, and drug development pipeline. De Germay said China now accounts for 40% of all clinical studies in oncology globally. That is a striking figure, especially because oncology remains one of the most competitive and financially important areas of drug development.
Pfizer Inc. (NYSE: PFE) also pointed out that clinical development can move three times faster in China and at roughly half the cost compared with Europe. That is a major issue for pharmaceutical companies because drug development is expensive, slow, and risky. Any country or region that can support faster and cheaper clinical development becomes more attractive to global biopharma companies. De Germay added that China produced 28 innovative medicines in 2024, compared with 18 from Europe. His warning was direct: “We have to compete with the U.S., but we also have to compete with China,” and “the threat of China is reality.” For investors, this is not just a political or regional comment. It is a reminder that the global pharmaceutical race is changing, and Pfizer Inc. (NYSE: PFE) must compete in a market where innovation is no longer concentrated in the traditional Western hubs.
Reuters also reported that the U.S. Food and Drug Administration launched Operation TrialBlazer to speed up early-stage drug research. Pfizer Inc. (NYSE: PFE) Chief Oncology Officer Jeffrey Legos said at least 20% of patients in Pfizer Inc. (NYSE: PFE)’s late-stage studies are enrolled in the United States. That detail matters because the U.S. remains a critical market for clinical trials, regulatory approvals, and commercial launches. If the FDA can speed up early-stage research while maintaining safety and scientific standards, it could help major drugmakers like Pfizer Inc. (NYSE: PFE) remain competitive in the global innovation race. This also connects to the larger AI-powered healthcare theme because faster trials, better patient recruitment, advanced data analytics, and digital research tools can all help improve drug development productivity.
The trivia here is that drug development is no longer just a laboratory race. It is now a data race, a regulatory race, a talent race, and a global execution race. Pharmaceutical companies are increasingly using artificial intelligence, machine learning, real-world evidence, clinical trial analytics, and digital platforms to improve how drugs are discovered, tested, and brought to market. Pfizer Inc. (NYSE: PFE), as one of the largest biopharmaceutical companies in the world, has the scale to participate in that transformation. But it also faces the pressure of proving that it can generate strong post-pandemic growth and compete with faster-moving biotech ecosystems in China, the United States, and beyond.
Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes biopharmaceutical products worldwide. For investors looking for best healthcare stocks, pharmaceutical stocks to buy, oncology stocks, AI-powered healthcare stocks, and global drug development stocks, Pfizer Inc. (NYSE: PFE) remains a major name. Its valuation may look more modest than many high-growth healthcare stocks, but its global footprint, oncology exposure, and focus on innovation make Pfizer Inc. (NYSE: PFE) a stock that investors continue to monitor closely.
Click next to see the following stock...
